SurgiQuest Receives Prestigious Grant Award from Qualifying Therapeutic Discovery Program

Share Article

Medical Device Company offers significant technological advances in minimally invasive surgery

AirSeal, AnchorPort

SurgiQuest develops, manufactures, and markets innovative technology for minimally invasive surgery

“This funding will help SurgiQuest continue our research and development efforts in access surgery, creating new platforms, and allowing us to focus on clinical relevance and patient outcomes.”

SurgiQuest, Inc., headquartered in Orange CT, was recently awarded a grant award from the Qualifying Therapeutic Discovery Program (QTDP). The program was highly competitive with nearly seven thousand applicants vying for funding.

SurgiQuest received the grant for their efforts in further developing two breakthrough technology platforms, the AirSeal® and AnchorPort® minimally invasive surgery access systems. The AirSeal® System offers smokeless laparoscopy and stable pneumoperitoneum, which means no leakage of abdominal CO2 inflation throughout the entire laparoscopic surgical procedure. The AirSeal® System consists of an innovative trocar, a smoke evacuation filter and a control unit that re-circulates CO2, while constantly filtering and removing smoke-borne toxic pathogens and carcinogens during laparoscopic procedures.

The AirSeal® System offers continuous smoke evacuation with minimal scope smudging and fogging, providing excellent visibility, stable pneumoperitoneum, and unprecedented freedom of instrument maneuverability for surgeons.

SurgiQuest’s AnchorPort® system offers bladeless, optical tip entry with the world’s first and only trocar that self-adjusts to the patient’s abdominal wall thickness. The AnchorPort® cannula’s unique elastomeric design eliminates slippage out of the abdomen during surgery. These innovative trocars can also be used to perform single incision surgery, leaving behind a 1-inch belly button scar that will become almost invisible after the healing process.

“SurgiQuest partnered with alliantgroup, the nation’s premier provider of specialty tax services, during the application process. alliantgroup’s team of biotechnology and life sciences experts guided our company throughout each step of the process and ensured our application was of the highest quality,” said Kurt Azarbarzin, Founder and CEO. “This funding will help SurgiQuest continue our research and development efforts in access surgery, creating new platforms, and allowing us to focus on clinical relevance and patient outcomes.”

QTDP was part of the Patient Protection and Affordable Care Act of 2010 and provides a 50% tax credit or grant to biotech, pharmaceutical and other healthcare companies for qualified investments by eligible companies in taxable years beginning in 2009 and in 2010 in connection with qualifying projects.

In addition to SurgiQuest, Inc. development efforts, other qualifying projects included those designed to:

  • Treat or prevent diseases or conditions by conducting pre-clinical activities, clinical trials and clinical studies, or carrying out research protocols for the purpose of securing federal government approval by the FDA.
  • Diagnose diseases or conditions or to determine molecular factors related to diseases or conditions by developing molecular diagnostics to guide therapeutic decisions.
  • Develop a product, process or technology to further the delivery or administration of therapeutics.

For more information about SurgiQuest, please contact Sarah Domena, Marketing Coordinator at 203-799-2400 or visit http://www.surgiquest.com

For more information about alliantgroup, please call (713)877-9600 or go to http://www.alliantgroup.com

About SurgiQuest
SurgiQuest, Inc. is a private venture-backed company, founded in May 2006. It develops, manufactures, and markets innovative technology for minimally invasive surgery.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sarah Domena
SurgiQuest
877-799-1979 ext. 216
Email >
Visit website